Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00360503 · ClinicalTrials.gov registry record
Antimicrobial Resistance in Cystic Fibrosis (CF)
A clinical trial, sponsored by Seattle Children's Hospital.
- Completed
- Registry status
- 304
- Enrollment target
NCT00360503 is a clinical trial that has completed, run by Seattle Children's Hospital. The registered enrollment target is 304 participants.
The verdict
NCT00360503 has completed, sponsored by Seattle Children's Hospital.
- COMPLETED
- Registry status
- 304 participants
- Enrollment target
Study Summary
People with cystic fibrosis (CF) often develop chronic pulmonary infections which are caused by a variety of organisms, the most predominant being Pseudomonas aeruginosa. Antibiotics are important in managing CF lung infections. Antibiotic use in CF was altered about ten years ago with the approval of inhaled tobramycin, an aminoglycoside which is effective in treating P. aeruginosa. A decade later, CF clinicians are increasingly concerned about the likelihood of induction of aminoglycoside-resistance with prolonged use of inhaled tobramycin to treat chronic P. aeruginosa airway infections. The goal of this study is to examine the current microbiology and susceptibility of organisms from CF sputum, correlate it with antibiotic use, and compare it with previous data.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 304 participants |
| Start Date | 2006-03 |
| Est. Completion | 2008-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00360503
The ClinicalTrials.gov registry entry for NCT00360503 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 304 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seattle Children's Hospital, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00360503 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00360503 about?
NCT00360503 is a clinical study titled "Antimicrobial Resistance in Cystic Fibrosis (CF)". People with cystic fibrosis (CF) often develop chronic pulmonary infections which are caused by a variety of organisms, the most predominant being Pseudomonas aeruginosa. Antibiotics are important in managing CF lung infections. Antibiotic use in CF was altered about ten years ago with the approval ...
What is the current status of trial NCT00360503?
This trial is currently completed. The enrollment target is 304 participants. The study started on 2006-03. Estimated completion is 2008-06.
Who is sponsoring clinical trial NCT00360503?
This trial is sponsored by Seattle Children's Hospital, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.